🇩🇪

BioNTech

Public

mRNA giant expanding into gene editing

Best known for co-developing the Pfizer-BioNTech COVID-19 vaccine, BioNTech is expanding into gene editing and cell therapy. The German company is leveraging its mRNA platform for in vivo gene editing delivery and developing CRISPR-engineered CAR-T cells for cancer immunotherapy.

Founded2008

HQMainz, Germany

CEOUgur Sahin

TickerNASDAQ:BNTX

Total Funding$2.5B+

Pipeline

Drug / Program	Indication	Phase	Technology
BNT211	Solid Tumors (CLDN6+)	Phase 1/2	CAR-T + mRNA
BNT311	Solid Tumors	Phase 2	Immunotherapy
Individualized neoantigen therapy	Melanoma	Phase 2	mRNA

Key People

Ugur SahinCEO & Co-founder

Özlem TüreciCMO & Co-founder